gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CYTKHealthcarePharmaceuticals

Cytokinetics Inc. (CYTK)

$63.60+2.07%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$63.60▲ 6.68% in range
Nov 4, 2025Low $59.19 · High $87.26Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Cytokinetics closed at $63.60 on Nov 4, up 2.07%, 27.1% below its 52-week closing high. Volume of 2.9M shares was 1.92× its 20-day average (above normal).

Split-adjusted performance: +3.7% over one month, -15.0% over six months, +5.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $28.62M, down 57.1% from a year earlier, with a net margin of -694.4%.

Short interest was 18.6M shares at the Oct 15 settlement, down 3.6% from the prior report (15.4% of float, 8.7 days to cover).

Market cap$8.84B139.0M shares
Revenue · quarter$28.6M−57.1% YoY
Diluted EPS$-1.50—
P/E · TTM—P/S 130.7×
Net margin-694.4%Gross 90.5%
Dividend yieldNone
52-week range59.19 – 87.26−27.1% from high
Volume2.9M1.92× 20-day avg
Volatility · 60d32.0%Annualised
Short % of float15.4%8.7 days to cover
Net cash$18.6MCash $1.17B
Next earnings—Not scheduled
Split-adjusted performance
1W +3.8%1M +3.7%3M −21.8%6M −15.0%YTD +0.1%1Y +5.9%3Y +98.2%5Y +82.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum61
Revenue growth19
Net margin25
Value (low P/E)—
Size94

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short18.6M−3.6% vs prior
Days to cover8.7Settled Oct 15
% of float15.4%
Short vol. 10d57.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CYTKCytokinetics$63.60+2.07%−15.0%−57.1%−694.4%—$8.84B
ARWRArrowhead Research$61.65+3.56%−22.1%+171.0%−258.2%—$8.71BCompare
CORTCorcept Therapeutics$79.22−3.31%+51.9%+31.7%16.8%157.2$8.56BCompare
MDGLMadrigal Pharmaceuticals$400.43+1.04%−25.8%+50.1%12.9%—$9.25BCompare
SYRESpyre Therapeutics$99.04−0.23%+35.7%———$9.26BCompare
PTGXProtagonist Therapeutics$143.37+2.23%+37.9%+3749.2%76.3%111.9$9.28BCompare
TGTXTG Therapeutics$61.63+1.45%+46.8%+70.3%3.2%21.4$9.43BCompare
PRAXPraxis Precision Medicines$284.79+1.53%−15.8%———$7.95BCompare
ALKSAlkermes$45.89+0.44%+29.9%+21.8%3.4%—$7.70BCompare

News about Cytokinetics

All news →
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research · Oct 28, 2026▲ PositiveCytokinetics to Announce Third Quarter Results on November 4, 2026GlobeNewswire Inc. · Oct 21, 2026▲ PositiveCytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026GlobeNewswire Inc. · Oct 2, 2026▲ PositiveCytokinetics to Participate in September Investor ConferencesGlobeNewswire Inc. · Sep 2, 2026▲ PositiveCan CYTK's Aficamten Strengthen Its HCM Growth Prospects?Zacks Investment Research · Sep 2, 2026▲ Positive

Quick answers

What does Cytokinetics do?
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease.
What is CYTK's market cap?
$8.84B, based on the Nov 4 close of $63.60.
Does Cytokinetics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CYTK is sold short?
18.6M shares, 15.4% of float, as of Oct 15, 2026.
What sector is CYTK in?
Healthcare, in the Pharmaceuticals industry.

About Cytokinetics

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

HQ: South San Francisco, CA673 employeesListed Apr 29, 2004cytokinetics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology